POR
TIF
INO
MEDICALLY CONTROLLED WEIGHT LOSS
WITH IN CLINIC SUPPORT
WEIGHT LOSS
WHAT IS IT?
Weight loss injections work by making you feel less hungry and fuller for longer. With Obesity impacting nearly 30% of the population, weight loss medications is more and more in demand. The 2 major players in the UK are currently Mounjaro and Wegovy. Both are prescription only medication.
HOW IS IT ADMINISTERED?
Weekly injections into the stomach, arm or thigh.
WHAT IS THE DIFFERENCE?
Mounjaro contains the active ingredient tirzepatide, which uniquely activates both GLP-1 and GIP receptors. This dual action targets blood sugar control and weight loss for those with type 2 diabetes or seeking weight management. Mounjaro leverages tirzepatide rather than semaglutide for these dual metabolic benefits.
Wegovy's sole active ingredient is semaglutide. This compound specifically activates GLP-1 receptors to reduce appetite and calorie intake, promoting weight loss. In Wegovy, semaglutide mimics natural GLP-1 hormones that regulate appetite. This facilitates weight loss for those struggling with obesity or being overweight with related health conditions.
HOW DOES IT WORK?
We offer both Mounjaro and Wegovy. Following your in clinic assessment we will make recommendations based on your unique circumstances and goals. If you are a suitable candidate we will arrange your prescription and advise you on starting your treatment. All treatments come with in clinic support as well as help managing any side effects.
SIDE EFFECTS
Both Wegovy (semaglutide) and Mounjaro (tirzepatide) can effectively aid weight management. Mounjaro also helps manage type 2 diabetes. However, as with any medication, side effects may occur. Though there are some common side effects due to similar mechanisms of action, each medication also carries unique risks.
Wegovy's side effects may include:
Gastrointestinal problems - nausea, vomiting, diarrhoea etc, especially when starting treatment
Appetite changes
Injection site reactions - redness, swelling, pain
Less common but serious risks involve pancreatitis, gallbladder problems, low blood sugar in diabetics on other medications, kidney dysfunction, and potential thyroid C-cell tumour risk.
Mounjaro's side effects can involve:
Likewise gastrointestinal issues, appetite changes, injection site reactions
As a dual GLP-1/GIP agonist, side effects may broadly overlap those of GLP-1 drugs but with added considerations due to the dual action
Less common serious risks may also include pancreatitis, gallbladder disease, hypoglycemia for those on diabetic drugs, and kidney problems.
For both treatments, those with a history of thyroid cancer or related genetic markers should use caution and discuss with their doctor, although human risk has not been conclusively shown.
Staying updated on emerging safety data through discussions with one’s healthcare provider is wise when considering these medications.